LLY Jan 2025 1040.000 call
- Yahoo Finance Video
Can GLP-1 weight-loss drug manufacturers keep momentum up?
As GLP-1 weight-loss drugs have boosted several healthcare stocks, Jennison Associates Head of Global Equity Mark Baribeau joins Market Domination Overtime to discuss whether these companies can keep up the momentum. Baribeau points to Novo Nordisk (NVO) and Eli Lilly (LLY) as companies seeing major revenue growth and likely to split the market. He sees weight-loss and type 2 diabetes drugs as a "paradigm shift" that present huge opportunities for both companies. However, he notes that while consumer demand for these drugs is skyrocketing, Novo Nordisk and Eli Lilly "don't have the manufacturing capacity to keep up with demand. So the gating factor here is really supply. It's not demand." He adds that as manufacturing capacities expand, growth will accelerate, making the industry's backdrop look "very, very healthy." For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Melanie Riehl
- Barrons.com
How Alphabet Could Become the Next $3 Trillion Stock
The three members each boast a market value above $3 trillion through Wednesday’s close, while Alphabet’s is hovering around $2.177 trillion, according to Dow Jones Market Data. There are two classes of Alphabet stock that trade significant volume, but they trade for similar prices, around $181, and overall there are about 12.4 billion shares outstanding. Stock prices, and market values, are a function of earnings and valuation multiples.
- Investor's Business Daily
Mutual Funds Keep Buying Up Google, These 2 Other Big Caps
Google stock is a mutual fund favorite and is near a buy point. Two other leading growth stocks top the list of fund favorites.
